Journal of Inflammation Research (Sep 2022)

TYK2 in Immune Responses and Treatment of Psoriasis

  • Shang L,
  • Cao J,
  • Zhao S,
  • Zhang J,
  • He Y

Journal volume & issue
Vol. Volume 15
pp. 5373 – 5385

Abstract

Read online

Lin Shang,* Jiali Cao,* Siqi Zhao, Jingya Zhang, Yanling He Department of Dermatology, Capital Medical University Affiliated Beijing Chaoyang Hospital, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yanling He, Email [email protected]: Tyrosine kinase 2 (TYK2), a key part of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, plays an integral role in the differentiation and immune responses of intrinsic immune cells and regulates the mediation of cytokines. TYK2 leads to inflammatory cascade responses in the pathogenesis of immune-mediated inflammatory diseases (IMIDs), especially psoriasis. Small-molecule TYK2 inhibitors are considered to be an effective strategy for modulating psoriasis. Here, we attempt to review the pro-inflammatory mechanisms of the JAK-STAT signaling pathway, the regulatory roles of TYK2 in the pathogenesis of psoriasis, and provide updates on ongoing and recently completed trials of TYK2 inhibitors.Keywords: TYK2, psoriasis, Janus kinase-signal transducer and activator of transcription, autoimmunity, inhibition

Keywords